Chronic activation of GPR40 does not negatively impact upon BRIN-BD11 pancreatic β-cell physiology and function

Eloisa Aparecida Vilas-Boas1,2 · Noémie Karabacz2 · Gabriela Nunes Marsiglio-Librasil1 · Maira Melo Rezende Valle1 · Lisa Nalbach3 · Emmanuel Ampofo3 · Bruce Morgan4 · Angelo Rafael Carpinelli1 · Leticia Prates Roma2

Abstract
Background Free fatty acids (FFAs) are known for their dual effects on insulin secretion and pancreatic β-cell survival. Short-term exposure to FFAs, such as palmitate, increases insulin secretion. On the contrary, long-term exposure to saturated FFAs results in decreased insulin secretion, as well as triggering oxidative stress and endoplasmic reticulum (ER) stress, culminating in cell death. The effects of FFAs can be mediated either via their intracellular oxidation and consequent effects on cellular metabolism or via activation of the membrane receptor GPR40. Both pathways are likely to be activated upon both short- and long-term exposure to FFAs. However, the precise role of GPR40 in β-cell physiology, especially upon chronic exposure to FFAs, remains unclear.

Methods We used the GPR40 agonist (GW9508) and antagonist (GW1100) to investigate the impact of chronically modulating GPR40 activity on BRIN-BD11 pancreatic β-cells physiology and function.

Results We observed that chronic activation of GPR40 did not lead to increased apoptosis, and both proliferation and glucose-induced calcium entry were unchanged compared to control conditions. We also observed no increase in H2O2 or superoxide levels and no increase in the ER stress markers p-eIF2α, CHOP and BIP. As expected, palmitate led to increased H2O2 levels, decreased cell viability and proliferation, as well as decreased metabolism and calcium entry. These changes were not counteracted by the co-treatment of palmitate-exposed cells with the GPR40 antagonist GW1100.

Conclusions Chronic activation of GPR40 using GW9508 does not negatively impact upon BRIN-BD11 pancreatic β-cells physiology and function. The GPR40 antagonist GW1100 does not protect against the deleterious effects of chronic palmitate exposure. We conclude that GPR40 is probably not involved in mediating the toxicity associated with chronic palmitate exposure.

Keywords Lipotoxicity · GPR40 activation · β-cells · Palmitate

Introduction

Free fatty acids (FFAs) play a central role in cellular physiology as they are both components of biological membranes and an important cellular energy source. In pancreatic β-cells, FFAs can acutely enhance glucose-stimulated insulin secretion (GSIS) either by modulation of intracellular metabolism or via activation of specific G protein-coupled receptors (GPCRs) [1–4]. In contrast, chronic exposure of pancreatic β-cells to saturated FFAs leads to impaired insulin secretion, β-cell dysfunction and apoptosis, a condition that has been termed lipotoxicity [5–12].

Lipotoxicity is a complex condition and several different molecular mechanisms have been suggested to underlie chronic FFA toxicity in β-cells. These mechanisms include,
Fig. 1 Signaling pathways activated by FFA and GPR40 agonists.

(a) FFAs can enter the cells and be translocated to the mitochondria via carnitine palmitoyltransferase 1 (CPT1) to be oxidized by β-oxidation. Long- and very-long-chain fatty acids are oxidized in peroxisomes, which generates \( H_2 O_2 \). Long-chain saturated or unsaturated FFAs can also bind to Gq-G-protein-coupled receptor GPR40 located in the plasma membrane. Acute activation of GPR40 by FFAs or agonists as GW9508 activates the phospholipase C (PLC) / diacylglycerol (DAG) pathway, which, respectively, activates PKC and mobilizes calcium from the endoplasmic reticulum (ER), potentiating the insulin release. GPR40 activation also activates PKD1, which acts on actin filaments to increase insulin secretion. Both activation of PKC and the β-oxidation may lead to the production of reactive oxygen species (ROS) in the cytosol by the NADPH oxidase 2 (NOX2) complexes and by the electron transport chain in the mitochondrial matrix, respectively. Specific sensors for hydrogen peroxide (\( H_2 O_2 \)) targeted to the mitochondrial matrix (Mt-roGFP2-Orp1) or in the cytosol (roGFP2-Orp1) were used herein to assess the \( H_2 O_2 \) production by different compartments. (b) Fluorescence of BRIN-BD11 cells expressing roGFP2-Orp1 in the mitochondrial matrix (Mito) or in the cytosol (Cyto) following excitation at 405 nm or 488 nm and the ratio (405/488) after addition of 10 mM DTT or 50 μM \( H_2 O_2 \). Numbers represent the non-normalized ratio after addition of DTT or 50 μM \( H_2 O_2 \). (c) Response of Mt-roGFP2-Orp1 (e) or roGFP2-Orp1 cells (d) expressed in BRIN-BD11 exposed to exogenously applied \( H_2 O_2 \) at the concentrations indicated concerning the impact of chronic GPR40 stimulation on β-cell function and fitness. Potential molecular mechanisms relating chronic GPR40 stimulation to changes in β-cell physiology are, thus, likewise very unclear. Consequently, the safety and efficacy of long-term use of GPR40 agonists in human patients remain an open question.

In this study, we sought to investigate the impact of chronic GPR40 activation on β-cell viability and function using the GPR40 agonist GW9508. Specifically, we focused on \( Ca^{2+} \) homeostasis, induction of UPR and changes in intracellular \( H_2 O_2 \) levels. Furthermore, we employed a GPR40 antagonist (GW1100) to investigate the role of GPR40 in the deleterious effects of chronic palmitate exposure. We observed that chronic GPR40 stimulation does not lead to changes in pancreatic β-cell viability, \( Ca^{2+} \) homeostasis, UPR induction or \( H_2 O_2 \) levels. Furthermore, we observed no protective effect of GRP40 inhibition in chronic palmitate exposure.

Results

Chronic activation of GPR40 signaling does not lead to increased \( H_2 O_2 \) production

Acute GPR40 activation has been shown to lead to increased ROS production via NADPH oxidases. However, the impact of chronic GPR40 activation on cellular ROS production is unclear. We considered it plausible that a long-term stimulation of ROS production may be involved in the reported toxicity of chronic GPR40 activation by small molecule GPR40 agonists.

Many methods for measuring intracellular ROS are prone to artifacts, are not able to monitor dynamic changes in ROS levels, offer little insight into subcellular ROS distribution and have poor ROS species specificity. We, therefore, sought to use the genetically encoded \( H_2 O_2 \) sensor, roGFP2-Orp1, targeted to either the mitochondrial matrix or the cytosolic/nuclear to overcome some of these limitations and to gain insight into subcellular compartment-specific \( H_2 O_2 \) changes following chronic GPR40 activation [37, 38]. Specifically, we generated BRIN-BD11 cells stably expressing the mitochondrial matrix-targeted \( H_2 O_2 \) sensor, mito-roGFP2-Orp1, or the cytosolic/nuclear localized sensor, roGFP2-Orp1. First, we demonstrated successful expression of the mitochondrial and cytosolic/nuclear sensor in BRIN-BD11 cells following excitation at either 405 nm or 488 nm (Fig. 1b). Fluorescence microscopy revealed that both sensors respond as expected to disulfide reducing (10 mM DTT) and oxidizing (50 μM \( H_2 O_2 \)) conditions, as indicated by ratiometric changes in fluorescence emission intensity following excitation at either 405 nm or 488 nm, henceforth referred to as the 405/488 nm ratio (Fig. 1b).
Next, we developed a fluorescence plate reader-based assay to enable us to monitor dynamic changes in roGFP2-Orp1 oxidation and, thus, H$_2$O$_2$ levels. With this assay, we observed a dose-dependent increase in the 405/488 nm ratio and, therefore, in roGFP2-Orp1 oxidation in both the mitochondrial matrix (Fig. 1c) and the cytosol (Fig. 1d), following the exogenous addition of H$_2$O$_2$. We, therefore, conclude that both sensors are capable of reporting changes in H$_2$O$_2$ concentrations in BRIN-BD11 cells.

We next investigated whether chronic treatment of our sensor-expressing BRIN-BD11 cells, with the GPR40 agonist GW9508, leads to H$_2$O$_2$ changes. GW9508 is an agonist of the FFAs receptors GPR40 and GPR120, with 100-fold selectivity to GPR40 in comparison to GPR120 [19].

To assess H$_2$O$_2$ changes, we incubated BRIN-BD11 cells for 48 h with GW9508 and subsequently measured the 405/488 nm ratio of both mitochondrial matrix (Fig. 2a) and cytosol (Fig. 2b) targeted roGFP2-Orp1 sensors. Interestingly, in both compartments, we observed no change in roGFP2 oxidation and, therefore, no change in H$_2$O$_2$ levels. Furthermore, we incubated cells with the superoxide (O$_2^−$)-reactive small molecule dye, dihydroethidium (DHE). Similarly, we also observed no increase in DHE fluorescence in GW9508-treated cells (Fig. 2c). In contrast, chronic treatment with the GPR40 non-competitive antagonist, GW1100, led to significantly increased oxidation of the mitochondrial matrix (Fig. 2a) and cytosolic (Fig. 2b) roGFP2-Orp1 sensors, as well as an apparent increase in DHE fluorescence, although this was not statistically significant (Fig. 2c).
Acute palmitate exposure has been shown to increase ROS production both via activation of NADPH oxidases and mitochondrial respiration [2, 39–41] as well as by GPR40 activation [1–4]. Chronic palmitate exposure also leads to increased ROS [42, 43]; however, whether GPR40 is involved in this context is unclear. We were able to recapitulate the previously reported increased in ROS production upon chronic palmitate exposure. Specifically, after 48 h of palmitate treatment, we observed an increased oxidation of both mitochondrial matrix (Fig. 2a) and cytosolic (Fig. 2b) roGFP2-Orp1 sensors, as well as increased DHE fluorescence (Fig. 2c), supporting an increase in O$_2^-$ production and subsequent dismutation to H$_2$O$_2$.

Finally, we monitored cells treated with both GW1100 and palmitate in combination to test for any involvement of GPR40 in ROS production upon chronic palmitate treatment. For the mitochondrial matrix roGFP2-Orp1 sensor, we observed a similar increase in oxidation as for palmitate or GW1100 treatments alone (Fig. 2a). For the cytosolic roGFP2-Orp1 sensor, we observed an increase in oxidation larger than for that with palmitate or GW1100 treatments alone (Fig. 2b). With DHE we also observed a statistically significant increase in fluorescence emission compared to control (Fig. 2c). In conclusion, our results surprisingly indicate that chronic GPR40 inhibition, and not chronic activation, leads to increased O$_2^-$/$\text{H}_2\text{O}_2$ levels. Hence, we suggest that GPR40 activation is not involved in chronic palmitate exposure-induced O$_2^-$/$\text{H}_2\text{O}_2$ production.

**Chronic GPR40 activation or inhibition has no effect on cell viability**

We next tested whether chronic GPR40 activation or inhibition affects cell viability. We, therefore, treated BRIN-BD11 cells with GW9508 or GW1100 for 48 h and subsequently subjected the cells to three different assays to assess viability and proliferation. Using a flow cytometric-based assay for apoptotic cells (see materials and methods), we observed no decrease in the percentage of viable cells and no increase in the percentage of apoptotic or necrotic cells with either chronic GW9508 or GW1100 treatment (Fig. 3a–c). Likewise, immunostaining against Ki67, a marker of cellular proliferation, revealed no impact of GW9508 treatment (Fig. 3d, e). However, we did see a decrease in proliferation of cells chronically exposed to GW1100 (Fig. 3d, e). Finally, consistent with Ki67 staining data, a 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT)-based assay for cellular metabolic activity revealed no impact of chronic GW9508 treatment (Fig. 3f), but did show decreased metabolic activity following chronic GW1100 exposure (Fig. 3f).

We tested whether GPR40 has any role in the toxicity of chronic palmitate exposure on β-cell viability. We observed a strong and significant decrease in the number of viable cells and an increase in the number of apoptotic cells following chronic palmitate treatment (Fig. 3a, b), with no changes in the number of necrotic cells (Fig. 3c). However, co-treatment of cells with GW1100 had no effect on palmitate-induced apoptosis (Fig. 3b). Furthermore, we observed that both palmitate and GW1100, either alone or in combination, led to decreased proliferation (Fig. 3d, e) and decreased metabolic activity (Fig. 3f). Therefore, we conclude that palmitate-mediated β-cell apoptosis is probably not mediated through GPR40 activation. On the contrary, GPR40 inhibition appears to be detrimental to β-cell metabolic activity and proliferation, although the negative effects of GPR40 inhibition and palmitate treatment do not appear to be additive.

**GPR40 is not involved in the calcium response of BRIN-BD11 cells to glucose**

We were next interested to assess whether chronic GPR40 stimulation or inhibition affects the ability of BRIN-BD11 cells to respond to acute glucose addition. Increase in intracellular Ca$^{2+}$ upon glucose stimulation is directly involved in the mobilization and secretion of the insulin granules, thereby reflecting β-cell functionality. Therefore, we incubated BRIN-BD11 cells for 48 h with GW9508, GW1100, palmitate or palmitate in combination with GW1100. Subsequently, we used the Ca$^{2+}$ dye, Fura-2 AM, to monitor cytosolic Ca$^{2+}$ changes in response to acute addition of 20-mM glucose.

We analyzed two parameters: the resting Ca$^{2+}$ after culture in different conditions, which was calculated by averaging Ca$^{2+}$ in the first 5 min of measurement before the addition of glucose (Fig. 4b), and, the change in the Fura-2 AM fluorescence excitation ratio following 14 min of acute glucose treatment (Fig. 4c). Interestingly, GW1100, but not GW9508, led to a decrease in resting Ca$^{2+}$ levels. Palmitate treatment also led to a statistically significant decrease in resting Ca$^{2+}$ levels (Fig. 4a, b). However, chronic treatment with either GW9508 or GW1100 did not affect the ability of cytosolic Ca$^{2+}$ to respond to acute glucose treatment (Fig. 4a, c). In contrast, chronic treatment with palmitate abolished the cytosolic Ca$^{2+}$ response to acute glucose treatment (Fig. 4c). Co-treatment of cells with GW1100 and palmitate did not rescue the negative effects of palmitate on either resting Ca$^{2+}$ levels or the ability of Ca$^{2+}$ to respond to glucose (Fig. 4a–c). In summary, we conclude that chronic GPR40 activation or inhibition does not affect the ability of BRIN-BD11 cells to respond to acute glucose treatment.
Chronic activation of GPR40 does not negatively impact upon BRIN-BD11 pancreatic β-cell function and survival, decelerating disease progression and enhancing patient well-being.

GPR40 is a highly expressed FFA receptor that has been shown to promote insulin secretion in pancreatic β-cells in response to both FFAs and glucose [27]. Consequently, there has been considerable interest in the development of GPR40 agonists as a possible therapeutic agent for stimulating pancreatic β-cells and, thus, for treatment of T2DM. Several GPR40 agonists have demonstrated positive effects on glycemic control in rodents and humans [27, 28]. Nonetheless, some studies have indicated that chronic activation of GPR40 may be detrimental for β-cell fitness and therefore, on the contrary, GPR40 antagonists may be beneficial for T2DM treatment [15–17, 33–35]. Finally, there is considerable discussion concerning the role of GPR40 in fatty acid-induced β-cell toxicity [17, 44].

In this study, we were able to gain further insight into the impact of agonist and antagonist-based chronic activation and inhibition of GPR40 on BRIN-BD11 pancreatic β-cell function and viability, as well as the role of GPR40 in mediating the effects of chronic palmitate exposure. Principally, we found that agonist-based chronic activation of GPR40, did not lead to increased cell apoptosis nor did it lead to decreased cellular proliferation or loss of metabolic activity. Furthermore, it did not affect Ca²⁺ homeostasis or the response of Ca²⁺ to glucose and did not lead to increases in cytosolic or mitochondrial H₂O₂ nor to increased superoxide levels. Therefore, our data suggest that 48 h activation of GPR40 does not lead to cellular toxicity in BRIN-BD11 β-cells. Our results, therefore, do not support a negative role of chronic GPR40 activation on β-cells. In agreement, Wagner and colleagues have also shown that cells treated with another synthetic GPR40 agonist, TUG-469, did not show any indication of increased apoptosis. Furthermore, when incubated with PA, the GPR40 agonist TUG-469, protected INS-1E cells from apoptosis [45]. Although toxic effects of the GPR40 agonist TAK-875 on hepatic cells have been reported during phase III clinical trials, it is currently unclear if toxicity was confined to hepatic cells or affected other cells as well [36].

Interestingly, we show that chronic incubation of BRIN-BD11 cells with a GPR40 antagonist, GW1100, led to decreased cellular proliferation and metabolic activity. Furthermore, 48 h exposure to the antagonist also increased cytosolic and mitochondrial matrix H₂O₂ levels. Based on our data, we hypothesize that decreased cellular metabolism...
(and consequently NADPH levels, as suggested by MTT assay) could underlie the effects of GW1100 treatment on H$_2$O$_2$ production. This is plausible as NADPH is the ultimate source of reductive equivalents for many H$_2$O$_2$-scavenging enzymes. Therefore, the lack of NADPH might ultimately be responsible for increased H$_2$O$_2$ levels, as previously shown in pancreatic islets cultured with low glucose [46, 47]. These data are also in agreement with the toxic effects of another GPR40 antagonist TUG-761. When INS-1E cells were incubated with TUG-761, it led to increased apoptosis, which was not further augmented with co-incubation of palmitate [45].

It has recently been shown, using several different antagonists (ANT203, DC260126 or ANT825) as well as by GPR40 knockdown, that the GPR40 pathway mediates a palmitate-induced increase in mitochondrial respiration in Min6 cells and human islets [48]. The mechanism by which inhibition of GPR40 impacts upon respiration is not completely clear, but might involve PKC, Ca$^{2+}$ and production of signaling second messengers [48]. Here, we have also shown decreased metabolism upon GPR40 antagonism as well as lower resting Ca$^{2+}$ (Figs. 3f, 4b, respectively). Those changes could consequently directly impact on proliferation rate, as, for example, seen by decreased Ki67 staining in GW1100-treated cells (Fig. 3d, e). Finally, treatment with a GPR40 antagonist did not ameliorate any of the negative effects of chronic palmitate treatment and, therefore, in our cells, palmitate-induced toxicity is likely to be independent of GPR40 signaling.

In contrast to our results, several recent studies have suggested that antagonism of GPR40 may represent a more effective method for T2DM treatment as compared to GPR40 agonism [17, 34, 49]. This was supported by findings showing that GPR40-null mice were protected against insulin resistance under high-fat diet [15]. In addition, two different GPR40 inhibitors were shown to rescue the deleterious
Chronic activation of GPR40 does not negatively impact upon BRIN-BD11 pancreatic β-cell...

Effects of FFAs on insulin secretion and cell viability [17, 34]. In one study, Wu et al., also reported a small beneficial effect of GPR40 inhibition on palmitate-induced ER stress, contrary to our observations. It is currently unclear what underlies the opposing results of our study in comparison to those of others. However, differences in cell lines, palmitate concentration and the specific GPR40 antagonist molecule used might all play a role. Furthermore, the possibility for off-target effects of any small molecule antagonist cannot ever be fully excluded [17]. Furthermore, GPR40 antagonists have not been observed to promote better glucose levels or improvement in glucose tolerance in animal models [16].

Fig. 5 Expression of ER stress markers in BRIN-BD11 cells. Cells were divided into: control condition (Ctrl), 100-µM palmitate (PA), 20-µM GPR40 agonist GW9508 (GW9508), 10 µM GPR40 antagonist (GW1100), PA + GW1100 and were treated in media containing 10-mM glucose for 48 h. Western blot analysis was performed for the proteins of interest: p-eIF2α, CHOP and BiP, using α-tubulin as internal control. a Representative bands and respective α-tubulin. Densitometric analysis of western blot: p-eIF2α (b), CHOP (c) and BiP (d). Results are expressed as mean±SEM of 3–5 independent experiments. Two-way ANOVA followed by Tukey was used to compare Ctrl, PA, GW1100 and PA + GW1100; Student’s t test was used to compare Ctrl and GW9508. b There was a significant effect of PA ($F_{1,12} = 14.41$, $p = 0.0025$) and not GW1100 ($F_{1,12} = 2.691$, $p = 0.1269$). c There was a significant effect of PA ($F_{1,8} = 24.68$, $p = 0.0011$) and GW1100 ($F_{1,8} = 15.35$, $p = 0.0044$). d There was no significant effect of PA ($F_{1,15} = 0.04331$, $p = 0.8379$) or GW1100 ($F_{1,15} = 0.004461$, $p = 0.9476$). p values are shown on the graph and indicate the difference versus control or difference versus PA in brackets.
which, therefore, suggest they offer little advantage as an antidiabetic drug.

In summary, we provide evidence that chronic activation of GPR40 does not lead to decreased cell viability and function or to increased oxidative and ER stresses. Nonetheless, our data do support an important role for GPR40 signaling in β-cell physiology, as demonstrated by the deleterious effects of the antagonist GW1100. Our data support the targeting of GPR40 for the treatment of T2DM and we believe that more efforts to test different agonists in clinical trials should be taken.

Materials and methods

Reagents

Culture medium with or without phenol red (RPMI 1640), dihydroethidium (DHE), RIPA lysis buffer, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Fura-2 AM were obtained from Thermo Fischer Scientific (Waltham, MA, USA); palmitic acid was obtained from Sigma-Aldrich (St. Louis, MO, USA); GW9508 and GW1100 were obtained from Calbiochem/Merck Millipore (Billerica, MA, USA); ViaCount Reagent was obtained from Merck Millipore (Billerica, MA, USA); anti-p-eIF2-α (#9721S), anti-CHOP-10 (#2895S), anti-BiP (#3183), anti-α-tubulin (#3873) and anti-Ki67 (#12202) antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA); Alexa Fluor555-conjugated anti-rabbit antibody (#A21429) was obtained from Invitrogen (Carlsbad, CA, USA).

Stable expression of mito- or cyto-roGFP2-Orp1 in BRIN-BD11 cells

We have recently generated genetically encoded fluorescent protein redox sensors, which allow real-time measurements of defined redox species in intact living cells and animal models [50]. We are employing these cell lines in the context of a newly developed fluorescence plate-reader-based methodology that allows high-throughput screening of multiple different conditions. Herein, BRIN-BD11 cells expressing the genetically encoded H2O2 sensor roGFP2-Orp1 either in the mitochondrial matrix (Mito-roGFP2-Orp1 BRIN-BD11) or untargeted in the cytosol (roGFP2-Orp1 BRIN-BD11) were generated by lentivirus transduction. Briefly, HEK-293FT cells were transfected with pLPCX/mito-roGFP2-Orp1 or pLPCX/roGFP2-Orp1 (encoding the roGFP2-Orp1 probe with an N-terminal mitochondrial or non-targeted sequence) by calcium phosphate method. After 6 h of transfection, cells were washed twice with DMEM medium without supplements and transferred to fresh medium. After 48 h of transfection, supernatant was collected and passed through an Amicon column Spin-X 431,491 (Corning Inc., NY, USA). BRIN-BD11 cells (seeded at 3 × 10^5 cells per well in a 6-well plate overnight before experiment) were incubated with the virus-containing supernatant in RPMI medium (0.1% P/S, 8 µg/ml Polybrene and without FCS) overnight at 37 °C in a 5% CO2 atmosphere. Cells were then selected in a medium containing puromycin (1 µg/ml) for 2 weeks.

Culture and treatment of cell lines

BRIN-BD11 cells were grown in RPMI 1640 medium with 10% FCS, 0.1% P/S (100 U/ml penicillin, 0.1 mg/ml streptomycin) and 11.1 mmol/l D-glucose, pH 7.4, in a humidified atmosphere of 5% CO2/95% air at 37 °C. For flow cytometry assays (superoxide measurement and viability) and for western blot, cells were seeded at 6 × 10^4 cells per well in 500-µl medium in 24-well plates; for the MTT assay and assessment of H2O2, cells were seeded at 7 × 10^3 cells per well in 200-µl medium in 96-well plates; for the evaluation of proliferation by anti-Ki67 staining, cells were seeded at 2.5 × 10^3 cells per condition in 500-µl medium in glass coverslips placed in 24-well plates; for the measurement of Ca2+ levels, cells were seeded at 1 × 10^4 cells per condition in 1.5-ml medium in glass coverslips placed in 25 cm^2 petri dishes. Mito-roGFP2-Orp1 BRIN-BD11 and roGFP2-Orp1 BRIN-BD11 cells were used for the assessment of H2O2 production. For the assessment of H2O2 and Ca2+, experiments were performed in complete RPMI medium without phenol red to decrease background fluorescence. Cells were allowed to adhere overnight and then incubated for 48 h in different conditions: 100 µM of PA, 20 µM of the GPR40 agonist GW9508, 10 µM of the GPR40 antagonist GW1100 or 100 µM of PA + 10 µM GW1100. All treatments were 48 h. PA was diluted in 100% ethanol to prepare a stock solution with a concentration of 50 mM. For complete solubilization, the stock solutions were mixed thoroughly. Stock solutions were prepared fresh for each experiment. GW1100 and GW9508 were diluted in DMSO to prepare stock solutions of 10 mM and 20 mM, respectively.

Superoxide measurement

After 48 h exposure to treatment, cells were incubated with 40 µM of DHE dye for 20 min at room temperature. Cells were then washed with PBS and incubated with 100 µl of trypsin for 5 min at 37 °C. Trypsin was inactivated with 200 µl of complete RPMI medium and cells were transferred...
to a 96-well plate. Fluorescence was assessed by the flow cytometer Guava EasyCyte (Millipore). Values of each experiment were normalized by the respective control values (considered as 1).

**Hydrogen peroxide (H₂O₂) measurement**

Measurements of intracellular levels of H₂O₂ were performed in mito-roGFP2-Orp1 BRIN-BD11 and roGFP2-Orp1 BRIN-BD11 cells after 48 h exposure to the different conditions, using the CLARIOstar Microplate Reader (BMG LABTECH, Ortenberg, Germany). Temperature was set to 37 °C and atmospheric conditions were set to 5% CO₂ with the ventilation left open for O₂ to diffuse freely in the system (18.8% O₂). Cytosolic and mitochondrial roGFP emission was detected after excitation at 405 and 488 nm and emission at 500–530 nm. The ratio 405/488 nm was calculated and plotted against time using GraphPad Prism.

**Viability**

Cell viability after 48 h of treatment was assessed by ViaCount Reagent, which distinguishes between viable and non-viable cells (divided into apoptotic and necrotic/dead cells). Protocol was performed as previously described [51] and fluorescence was assessed by the flow cytometer Guava EasyCyte (Millipore).

**Proliferation**

The proliferation of the cells after 48 h of treatment was determined after immunostaining with anti-Ki67. After 48 h of incubation, the cells were fixed for 30 min in 4% paraformaldehyde (in PBS) and permeabilized for 10 min in PBS containing 0.2% Triton X-100 and 2% bovine serum albumin (BSA) at room temperature. Unspecific binding sites were blocked by incubation with 1% BSA in PBS for 15 min before cells were incubated overnight at 4 °C with the specific anti-Ki67 primary antibody. After washing with PBS, cells were incubated with secondary Alexa Fluor555-conjugated anti-rabbit antibody for 1 h at room temperature. Subsequently, the cells were washed and incubated for 15 min at 37 °C with 3.7% bisBenzimide solution to stain the nuclei and finally sealed with mounting media. Images were captured by fluorescence microscopy (BX60F: OlympusOptical, Tokyo, Japan) and quantified at ImageJ Fiji Software.

**MTT assay**

The metabolic activity of cells after 48 h of treatment was determined using the MTT assay, as described by the manufacturer. Briefly, after addition of the MTT reagent to the samples, the purple formazan crystals formed were dissolved in DMSO and the absorbance was read at 570 nm on the microplate reader Synergy H1 (Biotek, Vermont, USA).

**Ca²⁺ measurements**

For the analysis of cytosolic calcium after 48 h of treatment, BRIN-BD11 cells were loaded with 2-µM Fura-2 AM for 25 min in a bicarbonate-buffered Krebs solution and placed under the microscope Axio Observer 7 (Zeiss, Oberkochen, Germany). Measurements were made every 2 s for 15 min during two steps: first in buffer without glucose, followed by addition of high glucose (20 mM). Cells were imaged using excitation 340/380 nm and emission 505 nm.

**Western blot**

Protein expression of ER stress markers was assessed by western blot. Total protein extracts were separated by SDS-PAGE and transferred to nitrocellulose membranes. Membranes were probed with specific antibodies against p-eIF2-α, CHOP and BiP. Anti-α-tubulin was used as internal control.

**Statistical analyses**

Results are presented as mean ± SEM from at least three independent experiments. Statistical analysis was carried out at the GraphPad Prism seven software. Two-way ANOVA followed by Tukey was used to compare differences between the following groups: control, PA, GW1100 and PA + GW1100; Student’s t test was used to compare differences between control and GW9508. In the supplementary Fig. 2, one-way ANOVA followed by Dunnet was used. Confidence levels were set to p < 0.05. P values, F values and degree of freedom for the two-way ANOVA (column factor and row factor) are presented in the figure legends. P values for the Tukey post test or Student’s t-test are presented in the figures.

**Acknowledgements** Open Access funding provided by Projekt DEAL. LPR acknowledges generous funding from the Deutsche Forschungsgemeinschaft (SFB894 project A13 and SFB TRR219 project M04) in the context of the SFB894 and TRR219. EAVB was funded by the Deutsche Forschungsgemeinschaft in the context of the Priority Program SPP 1710 (grant number MO 2774/2-1). We would also like to acknowledge Marlene Santos da Rocha, Andrea Armbrüster, Sandra Janku and Caroline Bickelmann for excellent technical assistance. We thank Prof. Markus Hoth for reading the manuscript and giving valuable comments.
Author contributions EVB, ARC and LPR are responsible for conception and design of research; EVAB, LPR, NK, GNML, MMVR, LN and EA performed experiments and analyzed the data; EVAB, BM, LPR and ARC interpreted results of experiments; EVAB, BM and LPR prepared figures and drafted the manuscript; all authors revised and approved final version of manuscript.

Compliance with ethical standards

Conflict of interest The authors declare that they have no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Graciano MF, Valle MM, Kowluru A, Curi R, Carpinelli AR. Regulation of insulin secretion and reactive oxygen species production by free fatty acids in pancreatic islets. Islets. 2011;3(5):213–23.
2. Graciano MF, Valle MM, Curi R, Carpinelli AR. Evidence for the involvement of GPR40 and NADPH oxidase in palmitic acid-induced superoxide production and insulin secretion. Islets. 2013;5(4):139–48.
3. Nolan CJ, Madiraju MS, Delgighardo-Augusto V, Peyot ML, Prentki M. Fatty acid signaling in the beta-cell and insulin secretion. Diabetes. 2006;55(Suppl 2):S16–23.
4. Poitout V. The ins and outs of fatty acids on the pancreatic beta cell. Trends Endocrinol Metab. 2003;14(5):201–3.
5. El-Asaad W, Buteau J, Peyot ML, Nolan C, Roduit R, Hardy S, et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology. 2003;144(9):4154–63.
6. Karaskov E, Scott C, Zhang L, Teodoro T, Ravazzola M, Volchuk A. Chronic palmitate but not oleate exposure induces endoplasmic reticulum stress, which may contribute to INS-1 pancreatic beta-cell apoptosis. Endocrinology. 2006;147(7):3398–407.
7. Lai E, Bikopoulos G, Wheeler MB, Rozakis-Adcock M, Volchuk A. Differential activation of ER stress and apoptosis in response to chronically elevated free fatty acids in pancreatic beta-cells. Am J Physiol Endocrinol Metab. 2008;294(3):E540–E550550.
8. Cunha DA, Hekerman P, Ladríre L, Bazarra-Castro A, Ortis F, Wakeham MC, et al. Initiation and execution of lipotoxic ER stress in pancreatic beta-cells. J Cell Sci. 2008;121(Pt 14):2308–18.
9. Cnop M, Ladríre L, Igolo-Esteve M, MOURA RF, Cunha DA. Causes and cures for endoplasmic reticulum stress in lipotoxic beta-cell dysfunction. Diabetes Obes Metab. 2010;12(Suppl 2):S76–82.
10. Gehrmann W, Elsner M, Lenzen S. Role of metabolically generated reactive oxygen species for lipotoxicity in pancreatic beta-cells. Diabetes Obes Metab. 2010;12(Suppl 2):149–58.
11. Maris J, Robert S, Waclkens E, Derua R, Hernangomez MH, D’Hertog W, et al. Role of the saturated nonesterified Fatty Acid palmitate in Beta cell dysfunction. J Proteome Res. 2013;12(1):347–62.
12. Gehrmann W, Würdemann W, Plötz T, Jörns A, Lenzen S, Elsner M. Antagonism Between Saturated and Unsaturated Fatty Acids in ROS Mediated Lipotoxicity in Rat Insulin-Producing Cells. Cell Physiol Biochem. 2015;36(3):852–65.
13. Michalska M, Wolf G, Walther R, Newsholme P. Effects of pharmacological inhibition of NADPH oxidase or iNOS on pro-inflammatory cytokine, palmitic acid or H2O2-induced mouse islet or clonal pancreatic beta-cell dysfunction. Biochim Rep. 2010;30(6):445–53.
14. Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab. 2006;291(2):E275–E281281.
15. Steneberg P, Rubins N, Bartoor-Shifman R, Walker MD, Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. 2005;1(4):245–58.
16. Zhang X, Yan G, Li Y, Zhu W, Wang H. DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats. Biomed Pharmacothe. 2010;64(9):647–51.
17. Wu J, Sun P, Zhang X, Liu H, Jiang H, Zhu W, et al. Inhibition of GPR40 protects MIN6 beta cells from palmitate-induced ER stress and apoptosis. J Cell Biochem. 2012;113(4):1152–8.
18. Itoh Y, Hinuma S. GPR40, a free fatty acid receptor on pancreatic beta-cells, regulates insulin secretion. Hepatol Res. 2005;33(2):171–3.
19. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem. 2003;278(13):11303–11.
20. Shapiro H, Shachar S, Sekler I, Hershinkel M, Walker MD. Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochem Biophys Res Commun. 2005;335(1):97–104.
21. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, et al. Free fatty acids regulate insulin secretion from pancreatic beta-cells through GPR40. Nature. 2003;422(6928):173–6.
22. Fujiwara K, Maekawa F, Yada T. Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Am J Physiol Endocrinol Metab. 2005;289(4):E670–E67767.
23. Negoro N, Sasaki S, Mikami S, Ito M, Suzuki M, Tsujihata Y, et al. Discovery of TAK-875: A Potent, Selective, and Orally bioavailable GPR40 Agonist. ACS Med Chem Lett. 2010;1(6):290–4.
24. Houze JB, Zhu L, Sun Y, Akerman M, Qiu W, Zhang AJ, et al. AMG 837: a potent, orally bioavailable GPR40 agonist. Bioorg Med Chem Lett. 2012;22(2):1267–70.
25. Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(3):271–8.
26. Mohammad S. GPR40 Agonists for the treatment of type 2 diabetes mellitus: benefits and challenges. Curr Drug Targets. 2016;17(11):1292–300.
27. Mancini AD, Poitout V. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol Metab. 2013;24(8):398–407.
28. Mancini AD, Poitout V. GPR40 agonists for the treatment of type 2 diabetes: life after ’TAKing’ a hit. Diabetes Obes Metab. 2015;17(7):622–9.
29. Naik H, Vakilynejad M, Wu J, Viswanathan P, Dote N, Higuchi T, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a
30. Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilnejad M, Xie B, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9824):1403–11.

31. Leifke E, Naik H, Wu J, Viswanathan P, Demanno D, Kipnes M, et al. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther. 2012;92(1):29–39.

32. Kaku K, Araki T, Yoshinaka R. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care. 2013;36(2):245–50.

33. Meidute Abaraviciene S, Lundquist I, Galvanovskis J, Flodgren E, Olde B, Salehi A. Palmitate-induced beta-cell dysfunction is associated with excessive NO production and is reversed by thiazolidinedione-mediated inhibition of GPR40 transduction mechanisms. PLoS ONE. 2008;3(5):e2182.

34. Kristinsson H, Smith DM, Bergsten P, Sargsyan E. FFAR1 is involved in both the acute and chronic effects of palmitate on insulin secretion. Endocrinology. 2013;154(11):4078–88.

35. Natalicchio A, Labarbora U, Tortosa F, Biondi G, Marrano N, Peschechera A, et al. Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway. Diabetologia. 2013;56(11):2456–66.

36. Menon V, Lincoff AM, Nicholls SJ, Jasper S, Wolski K, McGuire DK, et al. Fasiglifam-induced liver injury in patients with type 2 diabetes: results of a randomized controlled cardiovascular outcomes safety trial. Diabetes Care. 2018;41(12):2603–9.

37. Roma LP, Deponte M, Riemer J, Morgan B. Mechanisms and applications of redox-sensitive green fluorescent protein-based hydrogen peroxide probes. Antioxid Redox Signal. 2018;29(6):552–68.

38. Schwarzländer M, Dick TP, Meyer AJ, Morgan B. Dissecting redox biology using fluorescent protein sensors. Antioxid Redox Signal. 2016;24(13):680–712.

39. Morgan D, Oliveira-Emilio HR, Keane D, Hirata AE, Santos da Rocha M, Bordin S, et al. Glucose, palmitate and pro-inflammatory cytokines modulate production and activity of a phagocytolike NADPH oxidase in rat pancreatic islets and a clonal beta cell line. Diabetologia. 2007;50(2):359–69.

40. Carlsson C, Borg LA, Welsh N. Sodium palmitate induces partial mitochondrial uncoupling and reactive oxygen species in rat pancreatic islets in vitro. Endocrinology. 1999;140(8):3422–8.

41. Barlow J, Affourtit C. Novel insights into pancreatic beta-cell glucolipotoxicity from real-time functional analysis of mitochondrial energy metabolism in INS-1E insulinoma cells. Biochem J. 2013;456(3):417–26.

42. Sato Y, Fujimoto S, Mukai E, Sato H, Tahara Y, Ogura K, et al. Palmitate induces reactive oxygen species production and beta-cell dysfunction by activating nicotinamide adenine dinucleotide phosphate oxidase through Src signaling. J Diabetes Investig. 2014;5(1):19–26.

43. Fu J, Cui Q, Yang B, Hou Y, Wang H, Xu Y, et al. The impairment of glucose-stimulated insulin secretion in pancreatic beta-cells caused by prolonged glucotoxicity and lipotoxicity is associated with elevated adaptive antioxidant response. Food Chem Toxicol. 2017;100:161–7.

44. Shen X, Yang L, Yan S, Wei W, Liang L, Zheng H, et al. The effect of FFAR1 on pioglitazone-mediated attenuation of palmitic acid-induced oxidative stress and apoptosis in βTC6 cells. Metabolism. 2014;63(3):335–51.

45. Wagner R, Kaiser G, Gerst F, Christiansen E, Due-Hansen ME, Grundmann M, et al. Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. Diabetes. 2013;62(6):2106–11.

46. Deglasse JP, Roma LP, Pastor-Flores D, Gilon P, Dick TP, Jonas JC. Glucose acutely reduces cytosolic and mitochondrial H2O2 in rat pancreatic beta cells. Antioxid Redox Signal. 2019;30(3):297–313.

47. Takahashi HK, Santos LR, Roma LP, Duprez J, Broca C, Wojtusciszyn A, et al. Acute nutrient regulation of the mitochondrial glutathione redox state in pancreatic beta-cells. Biochem J. 2014;460(3):411–23.

48. Kristinsson H, Bergsten P, Sargsyan E. Free fatty acid receptor 1 (FFAR1/GPR40) signaling affects insulin secretion by enhancing mitochondrial respiration during palmitate exposure. Biochim Biophys Acta. 2015:1853(12):3248–57.

49. Sun P, Wang T, Zhou Y, Liu H, Jiang H, Zhu W, et al. DC260126: a small-molecule antagonist of GPR40 that protects against pancreatic beta-Cells dysfunction in db/db mice. PLoS ONE. 2013;8(6):e66744.

50. Fujikawa Y, Roma LP, Sobotta MC, Rose AJ, Diaz MB, Locatelli G, et al. Mouse redox histology using genetically encoded probes. Sci Signal. 2016;9(419):rs1.

51. Lucena CF, Roma LP, Graciano MF, Veras K, Simões D, Curi R, et al. Omega-3 supplementation improves pancreatic islet redox status: in vivo and in vitro studies. Pancreas. 2015;44(2):87–95.